Author:
Gazzard BG,Moyle GJ,Weber J,Johnson M,Bingham JS,Brettle R,Churchill D,Fisher M,Griffin G,Jefferies D,King E,Gormer R,Lee C,Pozniak A,Smith JR,Tudor-Williams G,Williams I
Reference40 articles.
1. Zidovudine alone or in combination with didanosine of zalcitabine in HIV-infected patients with the acquired immune deficiency syndrome or fewer than 200 CD4 cells per cubic millimeter;Saravolatz;N Engl J Med,1996
2. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200–500 per cubic millimeter;Hammer;N Engl J Med,1996
3. DELTA: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine or zidovudine alone in HIV infected individuals;Lancet,1996
4. Lalezari J, Haubrich R, Burger HU, et al. Improved survival and decreased disease progression of HIV in patients treated with saquinavir plus HIVID. XI International Conference on AIDS (Vancouver, July, 1996); LB.B.6033.
5. Katlama C on behalf of the CAESAR co-ordinating committee. Clinical and survival benefit of 3TC in combination with zidovudine-containing regimens in HIV-1 infection: interim results of the CAESAR study. 3rd International Congress on Drug Therapy in HIV Infection (Birmingham, UK, November, 1996): abstr SS2.1.
Cited by
210 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献